News & Events
2005 Press Releases
Eidogen-Sertanty License Kinase Database to Medisyn Technologies
San Diego, CA (September 7, 2005) - Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, today announced that they have licensed their Kinase Knowledgebase™ to Medisyn Technologies, a Minnesota-based early-stage drug discovery company. This announcement comes after the significant expansion of the Kinase Knowledgebase in July 2005, which now contains over 160,000 SAR data points and over 390,000 unique kinase compounds mined from scientific literature and patents. The Kinase Knowledgebase is Eidogen-Sertanty's database of structure-activity relationships (SAR) and chemical synthesis data focused on protein kinases - one of the most therapeutically important classes of drug targets.
Medisyn entered into an annual license agreement of the Kinase Knowledgebase after an initial validation of the data quality. "We were very pleased with the quality and comprehensiveness of Eidogen-Sertanty's kinase database," said David Land, President of Medisyn. "Medisyn's value lies in our ability to make drug discovery faster, less expensive and more predictable for biotechnology and pharmaceutical companies. The Kinase Knowledgebase broadens our palette of experimentally characterized compounds, saving preparation time and dollars in the application of our Fast Forward Engineering™ predictive discovery platform. We're optimistic that the data quality will contribute further efficiencies to our drug discovery process."
"We are excited to add Medisyn to our growing customer base. The fact that early stage platform-based drug discovery companies like Medisyn find value in our kinase database content highlights the universal applicability of our content across small, medium, and large drug discovery organizations," said Steve Muskal, CEO of Eidogen-Sertanty.
For more information, please contact:
Steve Muskal
760-651-2885
pr@eidogen-sertanty.com
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit www.eidogen-sertanty.com.
About Medisyn Technologies
Medisyn Technologies, Inc. is an early stage, privately held biotechnology company with a demonstrated approach to accelerating drug development by discovering and pre-qualifying novel lead compounds likely to move quickly through the drug development and approval process. Medisyn's predictive in silico Forward Engineering™ platform helps clients design new or improved drug candidates faster and more effectively than they can themselves through accurate prediction of drug safety, efficacy, potency, and mechanism of action. To find out more about collaborative opportunities with Medisyn Technologies, please visit www.medisyntech.com.